| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 42 | 2024 | 5264 | 5.010 |
Why?
|
| Interleukin-17 | 15 | 2024 | 251 | 4.560 |
Why?
|
| Carcinoma, Pancreatic Ductal | 24 | 2024 | 1833 | 4.260 |
Why?
|
| Microbiota | 5 | 2024 | 545 | 1.830 |
Why?
|
| Receptors, Interleukin-17 | 6 | 2024 | 26 | 1.410 |
Why?
|
| Gastrointestinal Microbiome | 6 | 2023 | 972 | 1.360 |
Why?
|
| Extracellular Traps | 4 | 2024 | 30 | 1.330 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 3054 | 1.070 |
Why?
|
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2024 | 33 | 0.950 |
Why?
|
| Bacteria | 4 | 2023 | 650 | 0.910 |
Why?
|
| Pancreas, Exocrine | 1 | 2023 | 23 | 0.840 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 1404 | 0.770 |
Why?
|
| Vitamin D | 1 | 2023 | 263 | 0.760 |
Why?
|
| Deoxycytidine | 6 | 2021 | 1389 | 0.750 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 163 | 0.730 |
Why?
|
| Adenocarcinoma | 5 | 2023 | 7920 | 0.720 |
Why?
|
| Germ-Line Mutation | 6 | 2024 | 1102 | 0.710 |
Why?
|
| Albumins | 3 | 2020 | 263 | 0.700 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2019 | 59 | 0.640 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2024 | 5779 | 0.630 |
Why?
|
| Mice | 37 | 2024 | 35421 | 0.620 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2018 | 30 | 0.600 |
Why?
|
| Bacterial Infections | 1 | 2021 | 510 | 0.580 |
Why?
|
| Chemokines, CXC | 4 | 2006 | 124 | 0.580 |
Why?
|
| Pneumonia, Pneumocystis | 4 | 2006 | 74 | 0.570 |
Why?
|
| Animals | 42 | 2024 | 61363 | 0.560 |
Why?
|
| Humans | 67 | 2024 | 270809 | 0.530 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 232 | 0.530 |
Why?
|
| Interleukins | 3 | 2015 | 340 | 0.530 |
Why?
|
| Colorectal Neoplasms | 5 | 2023 | 3707 | 0.520 |
Why?
|
| Epithelial Cells | 4 | 2024 | 1875 | 0.520 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 395 | 0.510 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 623 | 0.500 |
Why?
|
| Fluorouracil | 3 | 2021 | 1990 | 0.500 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 701 | 0.490 |
Why?
|
| Neoplasms | 6 | 2024 | 15952 | 0.490 |
Why?
|
| Pancreas | 4 | 2024 | 739 | 0.490 |
Why?
|
| Hematopoietic System | 1 | 2014 | 26 | 0.470 |
Why?
|
| Genetic Testing | 4 | 2024 | 1692 | 0.470 |
Why?
|
| Deoxycytidine Kinase | 1 | 2014 | 27 | 0.470 |
Why?
|
| Paclitaxel | 3 | 2020 | 2114 | 0.460 |
Why?
|
| ELAV Proteins | 1 | 2014 | 17 | 0.460 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 1345 | 0.460 |
Why?
|
| Signal Transduction | 6 | 2024 | 12036 | 0.450 |
Why?
|
| Interleukin-6 | 1 | 2018 | 1032 | 0.440 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2024 | 2454 | 0.430 |
Why?
|
| Receptors, Interleukin | 4 | 2018 | 97 | 0.430 |
Why?
|
| Immunotherapy | 8 | 2024 | 3561 | 0.430 |
Why?
|
| Carcinoma in Situ | 3 | 2024 | 489 | 0.410 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2015 | 290 | 0.390 |
Why?
|
| Neuroendocrine Tumors | 3 | 2024 | 656 | 0.390 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 2339 | 0.380 |
Why?
|
| Carcinogenesis | 4 | 2024 | 1034 | 0.380 |
Why?
|
| Precancerous Conditions | 4 | 2022 | 1061 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 9 | 2024 | 7054 | 0.370 |
Why?
|
| Pyruvic Acid | 3 | 2022 | 132 | 0.360 |
Why?
|
| Biomarkers | 3 | 2021 | 5050 | 0.360 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 1456 | 0.360 |
Why?
|
| Germ Cells | 2 | 2022 | 329 | 0.350 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2023 | 509 | 0.330 |
Why?
|
| Neutrophils | 4 | 2022 | 855 | 0.330 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2017 | 705 | 0.320 |
Why?
|
| Receptors, Chemokine | 2 | 2006 | 113 | 0.320 |
Why?
|
| Mice, Transgenic | 6 | 2024 | 4198 | 0.310 |
Why?
|
| BRCA1 Protein | 3 | 2021 | 528 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 3190 | 0.310 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 1437 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5582 | 0.300 |
Why?
|
| Interferon-gamma | 4 | 2006 | 1169 | 0.300 |
Why?
|
| BRCA2 Protein | 2 | 2021 | 380 | 0.300 |
Why?
|
| Mice, Knockout | 5 | 2024 | 5692 | 0.290 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1347 | 0.290 |
Why?
|
| 5'-Nucleotidase | 2 | 2024 | 63 | 0.290 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2023 | 481 | 0.280 |
Why?
|
| Cystic Fibrosis | 3 | 2008 | 291 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 16752 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5417 | 0.270 |
Why?
|
| Pneumocystis | 1 | 2005 | 15 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2005 | 657 | 0.250 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2009 | 587 | 0.250 |
Why?
|
| Cell Line, Tumor | 8 | 2022 | 14886 | 0.250 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 12045 | 0.250 |
Why?
|
| Betacoronavirus | 2 | 2020 | 514 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14639 | 0.240 |
Why?
|
| Bacteroides fragilis | 2 | 2018 | 7 | 0.240 |
Why?
|
| Carbon Isotopes | 3 | 2022 | 362 | 0.240 |
Why?
|
| Bronchi | 2 | 2007 | 325 | 0.240 |
Why?
|
| Inflammation | 7 | 2018 | 2491 | 0.240 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 425 | 0.230 |
Why?
|
| Pneumocystis carinii | 1 | 2004 | 20 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2006 | 1019 | 0.220 |
Why?
|
| Intestinal Polyposis | 1 | 2023 | 29 | 0.220 |
Why?
|
| Staining and Labeling | 2 | 2022 | 443 | 0.220 |
Why?
|
| Sexism | 1 | 2023 | 57 | 0.220 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3345 | 0.220 |
Why?
|
| Adenosine Deaminase | 1 | 2023 | 113 | 0.210 |
Why?
|
| Cell Proliferation | 2 | 2015 | 7233 | 0.210 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2022 | 20 | 0.210 |
Why?
|
| Male | 25 | 2024 | 128522 | 0.210 |
Why?
|
| Pancreatitis | 2 | 2023 | 296 | 0.200 |
Why?
|
| Adenoma | 2 | 2018 | 738 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 770 | 0.200 |
Why?
|
| Antibodies | 3 | 2022 | 802 | 0.200 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2023 | 165 | 0.200 |
Why?
|
| Interleukin-8 | 1 | 2024 | 528 | 0.200 |
Why?
|
| Biomarkers, Tumor | 4 | 2024 | 10731 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 98 | 0.200 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 691 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2022 | 1117 | 0.190 |
Why?
|
| Interferons | 1 | 2023 | 297 | 0.190 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 223 | 0.190 |
Why?
|
| Female | 21 | 2024 | 148940 | 0.180 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 249 | 0.180 |
Why?
|
| Lipocalin-2 | 1 | 2021 | 77 | 0.180 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 4320 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 606 | 0.180 |
Why?
|
| Genetic Counseling | 2 | 2024 | 417 | 0.180 |
Why?
|
| Colon | 2 | 2018 | 684 | 0.180 |
Why?
|
| Endogenous Retroviruses | 1 | 2020 | 47 | 0.180 |
Why?
|
| Polyamines | 1 | 2020 | 80 | 0.180 |
Why?
|
| Fungi | 1 | 2021 | 147 | 0.170 |
Why?
|
| Pancreatectomy | 2 | 2022 | 696 | 0.170 |
Why?
|
| Prognosis | 6 | 2024 | 22533 | 0.170 |
Why?
|
| Telemedicine | 2 | 2024 | 557 | 0.170 |
Why?
|
| Mutation Rate | 1 | 2020 | 220 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 7923 | 0.170 |
Why?
|
| Tumor Escape | 1 | 2021 | 247 | 0.170 |
Why?
|
| Aged | 11 | 2024 | 73641 | 0.160 |
Why?
|
| Metalloendopeptidases | 2 | 2018 | 171 | 0.160 |
Why?
|
| Immunization, Passive | 1 | 2020 | 179 | 0.160 |
Why?
|
| Dysbiosis | 1 | 2020 | 150 | 0.160 |
Why?
|
| Feces | 2 | 2020 | 852 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 5606 | 0.160 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2018 | 268 | 0.160 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 168 | 0.150 |
Why?
|
| Bacterial Toxins | 2 | 2018 | 218 | 0.150 |
Why?
|
| Octamer Transcription Factors | 1 | 2018 | 17 | 0.150 |
Why?
|
| Middle Aged | 12 | 2024 | 90570 | 0.150 |
Why?
|
| Cancer Vaccines | 2 | 2023 | 759 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 4900 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2022 | 669 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2022 | 316 | 0.150 |
Why?
|
| Disease Models, Animal | 7 | 2024 | 7323 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2019 | 9464 | 0.150 |
Why?
|
| Retinal Dehydrogenase | 1 | 2018 | 84 | 0.150 |
Why?
|
| Medical History Taking | 1 | 2018 | 175 | 0.150 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2018 | 104 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 879 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 4 | 2006 | 2419 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 1656 | 0.140 |
Why?
|
| B7-1 Antigen | 1 | 2017 | 84 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 1719 | 0.140 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 184 | 0.140 |
Why?
|
| Anilides | 1 | 2019 | 295 | 0.140 |
Why?
|
| ras Proteins | 2 | 2019 | 804 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 9048 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2021 | 697 | 0.140 |
Why?
|
| Pancreatitis, Chronic | 1 | 2018 | 130 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2396 | 0.140 |
Why?
|
| Genes, p53 | 1 | 2021 | 1140 | 0.140 |
Why?
|
| Intestinal Mucosa | 3 | 2023 | 1112 | 0.140 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 289 | 0.130 |
Why?
|
| Age of Onset | 1 | 2018 | 853 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2006 | 1044 | 0.130 |
Why?
|
| Mice, SCID | 5 | 2006 | 1825 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2018 | 228 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 1276 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 674 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2022 | 3040 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 31117 | 0.130 |
Why?
|
| Receptors, CXCR3 | 2 | 2006 | 34 | 0.130 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 2356 | 0.120 |
Why?
|
| Lung | 6 | 2019 | 3287 | 0.120 |
Why?
|
| Chemokine CXCL10 | 2 | 2006 | 104 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 1581 | 0.120 |
Why?
|
| Adult | 9 | 2024 | 82074 | 0.120 |
Why?
|
| Breast | 1 | 2021 | 1370 | 0.120 |
Why?
|
| Acinar Cells | 1 | 2014 | 56 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 750 | 0.120 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2014 | 19 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 1386 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 501 | 0.110 |
Why?
|
| Lymphocyte Depletion | 2 | 2006 | 316 | 0.110 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1096 | 0.110 |
Why?
|
| Physicians | 1 | 2022 | 854 | 0.110 |
Why?
|
| Risk Factors | 3 | 2021 | 17867 | 0.110 |
Why?
|
| Pandemics | 2 | 2020 | 1608 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 169 | 0.110 |
Why?
|
| Ribonuclease III | 1 | 2014 | 182 | 0.110 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 679 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 256 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2024 | 6766 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2014 | 251 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2014 | 162 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2022 | 39982 | 0.100 |
Why?
|
| Pyridines | 1 | 2019 | 1312 | 0.100 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2018 | 58 | 0.100 |
Why?
|
| Aspirin | 1 | 2014 | 373 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2014 | 702 | 0.100 |
Why?
|
| Protein Transport | 1 | 2014 | 738 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1064 | 0.100 |
Why?
|
| Adenoviridae | 3 | 2006 | 1490 | 0.100 |
Why?
|
| Phenotype | 1 | 2023 | 6503 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 542 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2023 | 5146 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2018 | 2261 | 0.090 |
Why?
|
| Prevalence | 1 | 2018 | 3395 | 0.090 |
Why?
|
| Disease Progression | 2 | 2021 | 6881 | 0.090 |
Why?
|
| Organoids | 2 | 2023 | 329 | 0.090 |
Why?
|
| Cell Polarity | 2 | 2014 | 211 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 1002 | 0.090 |
Why?
|
| Chemokines | 2 | 2008 | 285 | 0.090 |
Why?
|
| Spleen | 3 | 2008 | 719 | 0.080 |
Why?
|
| Interleukin-23 | 2 | 2008 | 28 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 12535 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2008 | 5658 | 0.080 |
Why?
|
| Age Factors | 1 | 2018 | 5443 | 0.080 |
Why?
|
| Chemokine CXCL1 | 2 | 2005 | 67 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2021 | 33860 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 12979 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 217 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2014 | 1715 | 0.080 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 316 | 0.080 |
Why?
|
| Immunity, Mucosal | 1 | 2008 | 118 | 0.070 |
Why?
|
| Klebsiella Infections | 1 | 2008 | 62 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 562 | 0.070 |
Why?
|
| Klebsiella pneumoniae | 1 | 2008 | 101 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2018 | 9281 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 4843 | 0.070 |
Why?
|
| Gene Expression | 1 | 2014 | 3606 | 0.060 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 70 | 0.060 |
Why?
|
| Macrophages, Peritoneal | 1 | 2005 | 70 | 0.060 |
Why?
|
| Leukocytes | 1 | 2008 | 420 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 2659 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2005 | 27 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 72 | 0.060 |
Why?
|
| Culture Media, Conditioned | 1 | 2005 | 254 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 5099 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 109 | 0.060 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 2038 | 0.060 |
Why?
|
| Immunologic Surveillance | 1 | 2024 | 59 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 193 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 1033 | 0.060 |
Why?
|
| Chemokine CXCL9 | 1 | 2004 | 24 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6259 | 0.060 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2004 | 85 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 235 | 0.060 |
Why?
|
| Taurine | 1 | 2023 | 24 | 0.060 |
Why?
|
| Ligands | 1 | 2006 | 1007 | 0.060 |
Why?
|
| Pseudomonas Infections | 1 | 2005 | 165 | 0.060 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 233 | 0.060 |
Why?
|
| Neutrophil Infiltration | 1 | 2004 | 105 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2019 | 1471 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 4054 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 358 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 800 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 15280 | 0.050 |
Why?
|
| Epithelium | 1 | 2005 | 786 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2017 | 104 | 0.050 |
Why?
|
| Serotonin | 1 | 2023 | 287 | 0.050 |
Why?
|
| Mutation | 4 | 2024 | 15922 | 0.050 |
Why?
|
| Kinetics | 1 | 2005 | 2206 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 10268 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 880 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 4470 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2021 | 1162 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2022 | 485 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 293 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2022 | 197 | 0.050 |
Why?
|
| Research Personnel | 1 | 2022 | 165 | 0.040 |
Why?
|
| X-linked Nuclear Protein | 1 | 2020 | 59 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 25 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2022 | 312 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 120 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2024 | 2618 | 0.040 |
Why?
|
| Cell Plasticity | 1 | 2020 | 67 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2021 | 4332 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2020 | 127 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2019 | 41 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1571 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 2986 | 0.040 |
Why?
|
| Family | 1 | 2024 | 782 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 236 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 266 | 0.040 |
Why?
|
| Intestines | 1 | 2023 | 727 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2019 | 112 | 0.040 |
Why?
|
| Cell Movement | 1 | 2006 | 2468 | 0.040 |
Why?
|
| CA-19-9 Antigen | 1 | 2019 | 155 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1587 | 0.040 |
Why?
|
| Probiotics | 1 | 2021 | 241 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 345 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2004 | 1837 | 0.040 |
Why?
|
| Neutralization Tests | 2 | 2009 | 236 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2020 | 649 | 0.040 |
Why?
|
| Macrophages | 1 | 2024 | 1334 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2018 | 157 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 906 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 1131 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2018 | 101 | 0.040 |
Why?
|
| Melanoma | 1 | 2015 | 5601 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2022 | 1273 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 312 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 454 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 5053 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2022 | 1724 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 396 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 16246 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 679 | 0.030 |
Why?
|
| Heterografts | 1 | 2019 | 739 | 0.030 |
Why?
|
| Anxiety | 1 | 2024 | 1244 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 925 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2018 | 274 | 0.030 |
Why?
|
| Glycolysis | 1 | 2019 | 529 | 0.030 |
Why?
|
| Cytokines | 2 | 2020 | 2804 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 1430 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 1536 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1221 | 0.030 |
Why?
|
| Colitis | 2 | 2009 | 340 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1216 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 1801 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 22255 | 0.030 |
Why?
|
| Depression | 1 | 2024 | 1733 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1469 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 443 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 1960 | 0.030 |
Why?
|
| Farnesol | 1 | 2012 | 16 | 0.030 |
Why?
|
| Salicylates | 1 | 2012 | 72 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 32698 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2560 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 5157 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 5313 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2019 | 2084 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2021 | 6344 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 5332 | 0.020 |
Why?
|
| T-Lymphocytes | 3 | 2008 | 3946 | 0.020 |
Why?
|
| Rats | 1 | 2019 | 6397 | 0.020 |
Why?
|
| Bacteroides Infections | 1 | 2009 | 10 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 4103 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 667 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2009 | 110 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5924 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3435 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 2922 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 650 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 5247 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 3656 | 0.020 |
Why?
|
| Joints | 1 | 2007 | 43 | 0.020 |
Why?
|
| Bronchiectasis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Cartilage | 1 | 2007 | 111 | 0.020 |
Why?
|
| Respiratory Mucosa | 1 | 2008 | 212 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2006 | 170 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 2033 | 0.020 |
Why?
|
| Chemokine CXCL5 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Proprotein Convertases | 1 | 2005 | 28 | 0.020 |
Why?
|
| Haplorhini | 1 | 2005 | 135 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2005 | 99 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 245 | 0.020 |
Why?
|
| Immune System | 1 | 2007 | 275 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2005 | 135 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 254 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2005 | 130 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 1023 | 0.020 |
Why?
|
| Antigens | 1 | 2005 | 279 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2050 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 590 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 923 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7647 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 1054 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3930 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 768 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 1503 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2005 | 585 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1553 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 1469 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 469 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 762 | 0.010 |
Why?
|
| Peptides | 1 | 2008 | 1502 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 2413 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 1101 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 1057 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 3187 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 1426 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 3041 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2008 | 3081 | 0.010 |
Why?
|